Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The AAMC Center for Health Justice will leverage community health partnership to drive health equity forward.

The AAMC, a leading national group representing medical colleges, has established a Center for Health Justice, acknowledging the role that medical education plays in establishing a future of health equity.

AAMC set up the AAMC Center for Health Justice as a part of its overall strategic plan for improving health equity and closing health disparities in communities across the country.

“Everyone has the right to the healthiest life possible. Health equity, however, is still not the reality for many communities across the country,” Philip M. Alberti, PhD, founding director of the AAMC Center for Health Justice, said in a statement.

Source: Patient Engagement HIT

https://patientengagementhit.com/news/medical-college-association-establishes-health-equity-center

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!